Market Intelligence, Clinical Progress, and High-Purity Reagents for Half-Life Extension and Albumin-Targeted Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ALB drug discovery and half-life extension platforms. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ALB Recombinant Protein (Human / Mouse / Cyno Orthologs). High purity (>95%), Endotoxin <1 EU/µg, Fatty Acid Free, Sequence Verified, HEK293 Expressed. | View ALB Products |
| Gene Delivery | ALB Promise-ORF / Lentivirus. Full-length ORF for hepatocyte stable cell line generation and secretion assays. | View ALB Products |
| Benchmark Ab | Anti-ALB (Albumin-Binding Domain Control). Recombinant positive control for PK/PD and binding assay calibration. | View ALB Products |
| Validator | ALB siRNA Set. For hepatocyte knockdown and assay specificity verification. | View ALB Products |
| Related Target: FCGRT | FcRn (FCGRT). FcRn-mediated recycling pathway; essential co-target for half-life engineering and pH-dependent binding studies. | View FCGRT Products |
| Related Target: SPARC | SPARC. Mediates albumin-bound nanoparticle tumor penetration and stromal accumulation. | View SPARC Products |
| Related Target: Cubilin | Cubilin (CUBN). Endocytic receptor for albumin uptake; validates targeting specificity. | View Cubilin Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species PK/PD evaluation (Human/Mouse/Cyno) | Human, Mouse, and Cyno ortholog ALB proteins available with >95% purity, Sequence Verified, Endotoxin Controlled. |
| Endosomal pH-dependent binding (SPR/BLI) | Theoretical MW verified, Native Glycosylation (HEK293 Expressed). Fatty Acid Free preparation ensures unoccupied drug-binding pockets. |
| Site-specific Conjugation Validation | Cys34-mutant variants (e.g., C34A background or engineered cysteines) available for thiol-chemistry validation. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included. |
| False Positives | Validated siRNA included for specificity checks. |
Live ALB R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ALB therapeutics and delivery systems is intensifying, with major players shifting focus from traditional mAbs to half-life extended peptides, nanobodies, and nanoparticle formulations. As first-generation therapies utilizing albumin-binding domains (ABDs) or fatty acid acylations reach the clinic, the next wave of R&D is targeting highly tuned pH-dependent albumin binding to maximize systemic circulation while ensuring efficient drug release at the target site.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Fatty Acid Acylated Peptides | Novo Nordisk, Eli Lilly | Metabolic Disorders (Diabetes/Obesity) | Affinity SPR Assay (Need high-purity Native ALB) |
| Albumin-Binding Nanobodies | Sanofi, Ablynx | Autoimmune, Oncology | pH-Dependent Binding (Need Endotoxin Controlled ALB) |
| Albumin Nanoparticles | BMS (Celgene) | Solid Tumors | Internalization Assay (Need High-purity Reagents) |
| Fusion Proteins | CSL Behring, Idorsia | Hematology, Rare Diseases | Selectivity Assay (Need Cross-reactive Abs) |
Key Functional Domains and Mutations
Albumin (ALB) is encoded by the ALB gene and comprises three homologous domains: Albumin 1, Albumin 2, and Albumin 3 (UniProt P02768). These domains are responsible for binding and transporting various endogenous and exogenous ligands, including fatty acids, bilirubin, and drugs. Key mutations include:
- Redhill/Malmo-I/Tradate: Associated in cis with T-344; dbSNP:rs800 (UniProt P02768 VAR_000499).
- Fukuoka-2/Lille/Taipei/Varese/Komagome-3: dbSNP:rs72552709 (UniProt P02768 VAR_000500).
- Jaffna: dbSNP:rs74821926 (UniProt P02768 VAR_000501).
These mutations are clinically relevant for understanding albumin variants and their impact on drug binding and pharmacokinetics.